Annovis Bio Inc
NYSE:ANVS
Intrinsic Value
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. [ Read More ]
The intrinsic value of one ANVS stock under the Base Case scenario is 5.5 USD. Compared to the current market price of 9.98 USD, Annovis Bio Inc is Overvalued by 45%.
Valuation Backtest
Annovis Bio Inc
Run backtest to discover the historical profit from buying and selling ANVS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Annovis Bio Inc
Current Assets | 10.2m |
Cash & Short-Term Investments | 5.8m |
Other Current Assets | 4.5m |
Current Liabilities | 4.3m |
Accounts Payable | 1.3m |
Accrued Liabilities | 3m |
Non-Current Liabilities | 13.7m |
Other Non-Current Liabilities | 13.7m |
Earnings Waterfall
Annovis Bio Inc
Revenue
|
0
USD
|
Operating Expenses
|
-45m
USD
|
Operating Income
|
-45m
USD
|
Other Expenses
|
-11.2m
USD
|
Net Income
|
-56.2m
USD
|
Free Cash Flow Analysis
Annovis Bio Inc
What is Free Cash Flow?
ANVS Profitability Score
Profitability Due Diligence
Annovis Bio Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Annovis Bio Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ANVS Solvency Score
Solvency Due Diligence
Annovis Bio Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Annovis Bio Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ANVS Price Targets Summary
Annovis Bio Inc
According to Wall Street analysts, the average 1-year price target for ANVS is 36.11 USD with a low forecast of 13.13 USD and a high forecast of 75.6 USD.
Ownership
ANVS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ANVS Price
Annovis Bio Inc
Average Annual Return | 31.12% |
Standard Deviation of Annual Returns | 97.12% |
Max Drawdown | -95% |
Market Capitalization | 105m USD |
Shares Outstanding | 11 010 000 |
Percentage of Shares Shorted | 18.02% |
ANVS News
Last Important Events
Annovis Bio Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Annovis Bio Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania and currently employs 3 full-time employees. The company went IPO on 2020-01-29. The firm is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The firm's lead compound, ANVS401, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The firm's ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as ANVS401, but it is given intravenously in cases of acute head and brain trauma. The firm is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.
Contact
IPO
Employees
Officers
The intrinsic value of one ANVS stock under the Base Case scenario is 5.5 USD.
Compared to the current market price of 9.98 USD, Annovis Bio Inc is Overvalued by 45%.